

INFLUENCE OF ANTIPYRETIC DRUGS ON THE LABELING OF BLOOD ELEMENTS WITH TECHNETIUM-99m

A. S. FONSECA,^{1*} J. N. G. FRYDMAN,² R. SANTOS¹ and M. BERNARDO-FILHO²

¹Departamento de Farmacologia e Psicobiologia e

²Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes,
Universidade do Estado do Rio de Janeiro,
Av. 28 de Setembro 87, fundos, 5º andar, 20551-030, Rio de Janeiro, Brasil

(Received: December 13, 2004; accepted: February 23, 2005)

Acetaminophen (AAP), acetylsalicylic acid (ASA) and dipyron (DIP) are antipyretic and analgesics drugs that have wide use in health sciences. Some drugs can modify the labeling of blood elements with technetium-99m (^{99m}Tc). This work has evaluated the effect of AAP, ASA and DIP on the labeling of the blood elements with ^{99m}Tc. Blood was incubated with different concentrations of the drugs before the ^{99m}Tc-labeled process. Plasma (P), blood cells (BC), insoluble (IF-P, IF-BC) and soluble (SF-P, SF-BC) fractions were separated and percentage of radioactivity (%ATI) in each fraction was determined. Data have shown that the antipyretic drugs used in this study did not significantly modify the fixation of ^{99m}Tc on the blood elements when the experiments were carried out with the doses usually used in human beings. Although the experiments were carried out with rats, it is possible to suggest that AAP, ASA or DIP should not interfere with the procedures in nuclear medicine involving the labeling of blood elements with ^{99m}Tc.

Keywords: Acetaminophen – acetylsalicylic acid – dipyron – blood elements – Technetium-99m

INTRODUCTION

Acetaminophen, acetylsalicylic acid and dipyron are antipyretics and analgesics of wide use and share in common several pharmacological actions of therapeutics interest. The antipyretic and analgesic actions of these drugs are based on inhibition of cyclooxygenase that is a enzyme responsible for the prostaglandin synthesis and some autacoids [6, 9, 10, 32]. Acetylsalicylic acid and dipyron present also antiinflammatory action by the same mechanism of their antipyretic and analgesics actions [2, 3, 39], while acetaminophen exhibits little or no antiinflammatory properties [33]. However, acetylsalicylic acid and dipyron can present a number of adverse effects at therapeutics doses as: (i) respiratory alkalosis with increased Na⁺, K⁺ and bicarbonate excretion [26, 29]; (ii) gastric ulceration, erosive gastritis, gastrointestinal hemorrhage and exacerbation of peptic ulcer symptoms [7, 25]; (iii) decreased urate excretion [18] and (iv) increased bleeding time, alterations in leukocyte and platelet

*Corresponding author; e-mail: adenilso@uerj.br

count [15, 21]. On other hand, the therapeutic use of acetaminophen is associated to: (i) erythematous or urticarial skin rash and [31] (ii) neutropenia and thrombocytopenia [8] and (iii) immunosuppression and hepatotoxicity [24].

The labeling efficiencies of blood elements with technetium-99m (^{99m}Tc) can be influenced by medicines [1, 23, 28, 35] or labeling conditions [4] and the presence of disease may be missed and/or underestimated [36].

Thus, data have shown that some drugs can modify the labeling of blood elements as red blood cells with ^{99m}Tc (^{99m}Tc -RBC) and alter the results obtained in the daily routine procedure in nuclear medicine laboratories [11, 14, 16]. High labeling yields and good *in vivo* stability of the *in vitro* labeling procedure give superior images, while *in vivo* labeling is more convenient and thus, quite widely used. In addition to pool imaging and other uses in nuclear cardiology, applications of ^{99m}Tc -RBC have also included diagnosis of deep vein thrombosis, gastrointestinal bleeding, hepatic hemangiomas and splenic reticuloendothelial system [4, 5, 23].

The aim of this work was to investigate the *in vitro* effects of acetaminophen, acetylsalicylic acid and dipyron on the labeling of blood elements with ^{99m}Tc .

MATERIALS AND METHODS

Animals

Adult male Wistar naive rats (3–4 months of age, body weight 250–350 g) were housed, five per cage, in an environment controlled room with inverted light/dark cycle conditions (12 h light/12 h dark; lights on at 6:00 a.m.), for an acclimatization period of at least 3 weeks. Animals had free access to water and food and ambient temperature was kept at 25 ± 2 °C. Experiments were conducted in accordance with the Department Committee of Animal Care.

Drugs

Acetaminophen and dipyron were purchased from Medley Indústria Farmacêutica (Brazil) and acetylsalicylic acid was purchased from Bayer (Brazil).

Study protocol

An *in vitro* technique employed to label RBC described elsewhere [4] was used with minor modification. Heparinized whole blood was withdrawn from Wistar rats. Samples of 0.5 ml were incubated with 100 μl of acetaminophen, acetylsalicylic acid or dipyron at different caffeine concentrations (10, 20, 100 and 10 000 $\mu\text{g}/\text{ml}$) for 1 h at room temperature. A sample of heparinized whole blood was incubated with NaCl 0.9% (Reagen, Rio de Janeiro, Brazil) as a control. Then, 0.5 ml of stannous

chloride (1.2 µg/ml) (Sigma Chemical Co., St. Louis, USA) was added and the incubation continued for another 1 h. After this period, ^{99m}Tc (0.1 ml), as sodium pertechnetate, recently milked from a $^{99}\text{Molybdenium}/^{99m}\text{Technetium}$ generator (Instituto de Pesquisas Energéticas e Nucleares, Comissão Nacional de Energia Nuclear, São Paulo, Brazil), was added and the incubation continued for another 10 minutes. These samples were centrifuged and plasma (P) and blood cells (BC) were separated. Samples (20 µl) of P and BC were precipitated with 1 ml of trichloroacetic acid (TCA) 5% and soluble (SF) and insoluble fractions (IF) were separated. The radioactivity in P, BC, IF-P, SF-P, IF-BC and SF-BC were determined in a well counter (Clinigamma, gamma counter, LKB, Wallac, Finland). After that, the percentage of radioactivity (%ATI) was calculated, as previously described [4].

Statistical analysis

Data are reported as means \pm SE of %ATI were compared between the treated and control groups by one-way analysis of variance-ANOVA, followed by Bonferroni post test with a $p < 0.05$ as significant level. InStat Graphpad software was used to perform statistical analysis (GraphPad InStat version 3.00 for Windows 95, GraphPad Software, San Diego California, USA).

RESULTS

The results in Table 1 show the percentage of radioactivity (%ATI) in blood cells (BC), plasma (P), insoluble and soluble fractions of plasma (IF-P and SF-P) and insoluble and soluble fractions of the blood cells (IF-BC and SF-BC) from whole blood treated with different concentrations of acetaminophen. The data presented in this table show that the treatment with this drug does not significantly ($p > 0.05$) modify the uptake of ^{99m}Tc by blood elements.

Table 2 shows %ATI in BC, P, IF-P, SF-P, IF-C and SF-C from whole blood treated with different concentrations of acetylsalicylic acid. The data presented in this

Table 1
Effect of acetaminophen on the labeling of blood elements with ^{99m}Tc

AP (µg/ml)	%ATI					
	BC	P	IF-P	SF-P	IF-C	SF-C
0	97.8 \pm 0.7	2.2 \pm 0.7	72.3 \pm 4.3	27. \pm 4.3	85.6 \pm 4.7	14.4 \pm 4.7
10	98.4 \pm 0.5	1.6 \pm 0.5	66.3 \pm 4.9	33.7 \pm 4.9	83.2 \pm 4.4	16.7 \pm 4.4
20	98.6 \pm 1.3	1.4 \pm 1.3	64.5 \pm 7.0	33.5 \pm 7.0	85.5 \pm 3.5	14.5 \pm 3.5
100	99.0 \pm 0.4	1.0 \pm 0.4	65.8 \pm 5.4	34.2 \pm 5.4	80.7 \pm 3.2	19.3 \pm 3.2
1000	98.3 \pm 0.6	1.7 \pm 0.6	62.6 \pm 7.6	37.4 \pm 7.6	82.6 \pm 5.1	17.4 \pm 5.1

Table 2
Effect of acetylsalicylic acid on the labeling of plasma proteins with ^{99m}Tc

AS ($\mu\text{g/ml}$)	%ATI					
	BC	P	IF-P	SF-P	IF-C	SF-C
0	97.8 \pm 0.7	2.2 \pm 0.7	72.3 \pm 4.3	27.7 \pm 4.3	85.6 \pm 4.7	14.4 \pm 4.7
10	97.7 \pm 0.3	2.3 \pm 0.3	70.3 \pm 5.0	29.7 \pm 5.0	86.1 \pm 4.9	13.9 \pm 4.9
20	98.3 \pm 0.3	1.7 \pm 0.3	68.9 \pm 4.4	31.1 \pm 4.4	85.3 \pm 5.4	14.7 \pm 5.4
100	97.1 \pm 0.8	2.9 \pm 0.8	71.5 \pm 4.3	28.5 \pm 4.3	84.6 \pm 5.4	15.4 \pm 5.4
1000	95.4 \pm 1.3	4.6 \pm 1.3	69.7 \pm 8.4	30.3 \pm 8.4	82.0 \pm 7.4	18.0 \pm 7.5

Table 3
Effect of dipyron on the labeling of plasma proteins with ^{99m}Tc

DP ($\mu\text{g/ml}$)	%ATI					
	BC	P	IF-P	SF-P	IF-C	SF-C
0	97.8 \pm 0.7	2.2 \pm 0.7	72.3 \pm 4.3	27.7 \pm 4.3	85.6 \pm 4.7	14.4 \pm 4.7
10	96.1 \pm 1.0	3.9 \pm 1.0	75.2 \pm 3.3	24.8 \pm 3.3	73.4 \pm 1.5*	26.6 \pm 1.5*
20	95.4 \pm 0.3	4.6 \pm 0.3	76.3 \pm 1.7	23.6 \pm 1.7	85.7 \pm 5.5	14.3 \pm 5.5
100	94.7 \pm 1.7	5.3 \pm 1.7	74.1 \pm 2.2	25.9 \pm 2.2	92.6 \pm 1.4	7.4 \pm 1.4
1000	94.1 \pm 1.3	5.9 \pm 1.3	84.6 \pm 1.4	15.4 \pm 1.4	93.3 \pm 1.3*	6.7 \pm 1.3*

* $p < 0.05$.

table show that the treatment with this drug also does not significantly modify the uptake of ^{99m}Tc by blood elements.

Table 3 shows the %ATI on BC, P, IF-P, SF-P, IF-BC and SF-BC from whole blood treated with the various concentrations of dipyron. The data presented in this table indicate that the treatment with this drug does not modify in important way the uptake of ^{99m}Tc in blood elements. However, at lowest and highest concentrations (10 and 1000 $\mu\text{g/ml}$) a slight alteration ($p < 0.05$) of the %ATI in insoluble (IF-BC) and soluble (SF-BC) fractions of blood cells was observed.

DISCUSSION

Therapeutic drugs can modify the nature or amount of the ^{99m}Tc -radiopharmaceutical bound to blood elements and result in unexpected behavior of the radiopharmaceutical [22, 23, 37, 42]. Thus, the evaluation of the influence of drugs on fixation of ^{99m}Tc in blood elements are important. However, the data from these studies are relatively scarce and the effects of pharmacologically active agents on the diagnostic by radiopharmaceuticals can be evaluated.

The data obtained in this work show that acetaminophen, acetylsalicylic acid and dipyron at concentrations used (10 up to 1000 $\mu\text{g/ml}$) did not modify the fixation of $^{99\text{m}}\text{Tc}$ in the blood elements (Tables 1, 2 and 3). The lowest effective plasma concentrations of acetaminophen and acetylsalicylic acid were 10 and 150 $\mu\text{g/ml}$, respectively [20]. Toxic concentrations of acetaminophen were higher than 300 $\mu\text{g/ml}$ [20] while toxicity of acetylsalicylic acid in human is obtained with 200 $\mu\text{g/ml}$ [20]. It was verified [40] that the maximum plasma concentration of dipyron in humans was about 13.4 $\mu\text{g/ml}$ at an oral dose of 480 mg after 1 up to 1.5 hours of administration. Thus, the results obtained in this work showed that these drugs in the plasma concentrations applied in humans did not alter the uptake of the $^{99\text{m}}\text{Tc}$.

Acetaminophen has been described to induce haematologic and hepatocellular oxidative stress [43]. On the other hand, this drug has been shown to inhibit the leukocyte myeloperoxidase antimicrobial system and, under certain experimental conditions, can act as an antioxidant inhibiting the myeloperoxidase-hydrogen peroxide-nitrite mediated modification of low density lipoprotein [13] and can reduce lipid peroxidation associated with decreased progression of atherosclerosis [12]. However, these possible effects of acetaminophen have not affect the fixation of $^{99\text{m}}\text{Tc}$ on red blood elements under conditions studied in this work.

Several effects of acetylsalicylic acid have been associated to antioxidant properties [38, 44]. However, other authors have showed that when this drug is given orally, its main metabolite is the salicylic acid that presents antioxidant effect higher than acetylsalicylic acid [19]. Thus, the absence of effect of acetylsalicylic on uptake of $^{99\text{m}}\text{Tc}$ by red blood cells may be related to its short antioxidant effect.

The data presented in Table 3 indicate that dipyron at the lowest and highest concentrations used (10 and 1000 $\mu\text{g/ml}$, respectively) may modify the fixation of the $^{99\text{m}}\text{Tc}$ on in insoluble and soluble fractions of blood cells proteins (IF-BC and SF-BC). However, in intermediary concentrations (20 and 100 $\mu\text{g/ml}$), dipyron did not alter the fixation of $^{99\text{m}}\text{Tc}$ on blood elements as shown in Table 3. Thus, the data we obtained showed that dipyron in the plasma concentrations applied to humans as therapeutic doses could not alter the uptake of the $^{99\text{m}}\text{Tc}$.

The agranulocytosis induced by dipyron may involve metabolic activation to reactive intermediates by hypochlorite formed by myeloperoxidase in activated neutrophils [27, 41]. In addition, it was observed that dipyron radicals formed by peroxidase action cause GSH, NADH or arachidonate oxidation and in this process reactive oxygen species are produced [17]. Thus, the little influence of dipyron on the fixation of $^{99\text{m}}\text{Tc}$ on cell protein fractions observed at the lower and the higher concentrations used may be related to production of free radicals.

Another possibility that may explain the possible dipyron effect on fixation of $^{99\text{m}}\text{Tc}$ on plasma protein fractions is the competition between this drug and the radionuclide for the same binding site. This hypothesis is based on other data that suggested that the labeling of blood elements with $^{99\text{m}}\text{Tc}$ should be altered by some drugs or extracts of plants [16, 30, 34].

In conclusion, the data presented in this work showed that acetaminophen, acetylsalicylic acid and dipyron in concentrations usually found in the plasma of humans did not modify the labeling of blood elements with ^{99m}Tc in rats.

REFERENCES

1. Almeida, Catanho, M. T., Cavalcanti, Jales, R. L., Cardoso, V. N., Bernardo-Filho, M. (2003) Assessment of the effect of *Fucus vesiculosus* extract on the labeling of blood constituents with technetium-99m and the histological modifications on the shape of the red blood cells. *Food Chem. Toxicol.* 41, 15–20.
2. Amann, R., Peskar, B. A. (2002) Anti-inflammatory effects of aspirin and sodium salicylate. *Eur. J. Pharmacol.* 447, 1–9.
3. Aude, Y. W., Mehta, J. L. (2002) Nonplatelet-mediated effects of aspirin. *Drugs Today (Barc)* 38, 501–507.
4. Bernardo-Filho, M., Gutfilen, B., Maciel, O. S. (1994) Technetium-99m binding on plasma proteins and red blood cells: role of various precipitating agents. *Biomed. Lett.* 50, 17–24.
5. Bernardo-Filho, M., Moura, I. N. S., Boasquevisque, E. M. (1983) ^{99m}Tc -labeled red blood cells “in vitro”. *Arch. Biol. Technol.* 26, 455–461.
6. Bigal, M. E., Bordini, C. A., Speciali, J. G. (2002) Intravenous dipyron for the acute treatment of episodic tension-type headache: a randomized, placebo-controlled, double-blind study. *Braz. J. Med. Biol. Res.* 35, 1139–1145.
7. Bollini, P., Garcia Rodriguez, L. A., Perez Gutthann, S., Walker, A. M. (1992) The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. *Arch. Intern. Med.* 152, 1289–1295.
8. Bougie D., Aster, R. (2001) Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. *Blood* 97, 3846–3850.
9. Boutaud, O., Aronoff, D. M., Richardson, J. H., Marnett, L. J., Oates, J. A. (2002) Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. *Proc. Nat. Acad. Sci. USA* 99, 7130–7135.
10. Catella-Lawson, F. (2001) Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. *Neurology* 57 (supp 2), S5–S7.
11. Capriles, P. V., Dias, A. P., Costa, T. E., Oliveira, M. B., Faria, M. V., Moura, E. G., Abreu, B. A., Bernardo-Filho, M. (2002) Effect of eggplant (*Solanum melongena*) extract on the in vitro labeling of blood elements with technetium-99m and on the biodistribution of sodium pertechnetate in rats. *Cel. Mol. Biol.* 48, 771–776.
12. Chong, P. H., Kezele, B., Pontikes, P. J. (2001) Effect of acetaminophen on atherosclerosis. *Ann. Pharmacother.* 35, 1476–1479.
13. Chou, T. M., Greenspan, P. (2002) Effect of acetaminophen on the myeloperoxidase-hydrogen peroxide-nitrite mediated oxidation of LDL. *Biochem. Biophys. Acta* 1581, 57–63.
14. de Oliveira, J. F., Avila, A. S., Braga, A. C., de Oliveira, M. B., Boasquevisque, E. M., Jales, R. L., Cardoso, V. N., Bernardo-Filho, M. (2002) Effect of extract of medicinal plants on the labeling of blood elements with Technetium-99m and on the morphology of red blood cells: I – a study with *Paullinia cupana*. *Fitoterapia* 73, 305–312.
15. Edwards, J. E., McQuay, H. J. (2002) Dipyron and agranulocytosis: what is the risk? *Lancet* 360 (9344), 1438.
16. Frydman, J. N. G., Oliveira, M. B. N., Santos, A. E. O., Fonseca, A. S., Santos, R., Bernardo-Filho, M. (2004) Influence of methylxanthines on the labeling of blood elements with ^{99m}Tc . *Pak. J. Biol. Sci.* 4, 521–524.
17. Galati, G., Tafazoli, S., Sabzevari, O., Chan, T. S., O’Brien, P. J. (2002) Idiosyncratic NSAID drug induced oxidative stress. *Chem-Biol. Interact.* 142, 25–41.

18. Gascon, N., Otal, C., Martínez-Bru, C., Merce, J., Cortes, M., Arcelus, R., Queralto, J. M., Sanchez, J. M., Gonzalez-Sastre, F. (1993) Dipyron interference on several common biochemical tests. *Clin. Chem.* 39, 1033–1036.
19. Guerrero, A., González-Correa, J. A., Arrebola, M. M., Muñoz-Marín, J., Sánchez De La Cuesta, F., De La Cruz, J. P. (2004) Antioxidant effects of a single dose of acetylsalicylic acid and salicylic acid in rat brain slices subjected to oxygen-glucose deprivation in relation with its antiplatelet effect. *Neurosci. Lett.* 358, 153–156.
20. Hardman, J. G., Limbird, L. E., Gilman, A. G. (2001) *Goodman & Gilman's: The Pharmacological Basis of Therapeutics*. 10th ed. McGraw-Hill, New York.
21. Hedenmalm, K., Spigset, O. (2002) Agranulocytosis and other blood dyscrasias associated with dipyron (metamizole). *Eur. J. Clin. Pharmacol.* 58, 265–274.
22. Hesselwood, S., Leung, E. (1994) Drug interactions with radiopharmaceuticals. *Eur. J. Nucl. Med.* 21, 348–356.
23. Hladik, W. B., Ponto, J. A., Lentle, B. C., Laven, D. L. (1987) Iatrogenic alterations in the biodistribution of radiotracers as a result of drug therapy: reported instances. In: *Essentials of Nuclear Medicine Sciences*. Williams and Wilkins, Sydney, 199–202.
24. Jaeschke, H., Knight, T. R., Bajt, M. L. (2003) The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. *Toxicol. Lett.* 144, 279–288.
25. Langman, M. J., Weil, J., Wainwright, P., Lawson, D. H., Rawlins, M. D., Logan, R. F., Murphy, M., Vessey, M. P., Colin-Jones, D. G. (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. *Lancet* 343(8905), 1075–1078.
26. Lauwerys R., Bernard, A. (1989) Preclinical detection of nephrotoxicity: description of the tests and appraisal of their health significance. *Toxicol. Lett.* 46, 13–29.
27. Miyamoto, G., Zahid, N., Uetrecht, J. P. (1997) Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. *Chem. Res. Toxicol.* 10, 414–419.
28. Nigri, F., Oliveira, M. B., Bernardo-Filho, M. (2002) Assessment of the effect of antiseizure drugs on the labeling process of red blood cells and plasma proteins with technetium-99m. *Cell. Mol. Biol. (Noisy-le-grand)* 48, 793–801.
29. Nuyts, G. D., Elseviers, M. M., De Broe, M. E. (1989) Health impact of renal disease due to nephrotoxicity. *Toxicol. Lett.* 46, 31–44.
30. Oliveira, J. F., Braga, A. C. S., Ávila, A. S., Fonseca, L. M. B., Gutflen, B., Bernardo-Filho, M. (1996) Effect of *Thuya occidentalis* on the labeling of red blood cells and plasma proteins with technetium-99m. *Yale J. Biol. Med.* 69, 489–494.
31. Porto Arceo, J. A. (2003) Special features of NSAID intolerance in children. *Allerg. Immunopathol. (Madri)*, 31: 109–125.
32. Prado, W. A., Pontes, R. M. (2002) Presurgical ketoprofen, but not morphine, dipyron, diclofenac or tenoxicam, preempts post-incisional mechanical allodynia in rats. *Braz. J. Med. Biol. Res.* 35, 111–119.
33. Robak, J., Kostka-Trabka, E., Duniec, Z. (1980) The influence of three prostaglandin biosynthesis stimulators on carrageenin-induced edema of rat paw. *Biochem. Pharmacol.* 29, 1863–1865.
34. Rusckowski, M., Qu, T., Chang, F., Hnatowich, D. J. (1997) Technetium-99m labeled epidermal growth factor-tumor imaging in mice. *J. Pept. Res.* 50, 393–401.
35. Sampson, C. B. (1996) Complications and difficulties in radiolabeling blood cells: a review. *Nucl. Med. Commun.* 17, 648–658.
36. Santos, J. S., Paula, E. F., Correa, T. G., Freitas, L. C., Fonseca, L. M. B., Gutflen, B., Bernardo-Filho, M. (1995) Effect of cyclophosphamide on the binding of $^{99m}\text{TcO}_4^-$ and $^{99m}\text{Tc-MDP}$ to blood cells and plasma proteins. *Braz. J. Med. Biol. Res.* 28, 131–135.
37. Sobal, G., Sinzinger, H. (2001) Methylene blue-enhanced stability of (99mTc)HMPAO and simplified quality control – a comparative investigation. *Appl. Radiat. Isotopes* 54, 633–636.
38. Steer, K. A., Wallace, T. M., Bolton, C. H., Hartog, M. (1997) Aspirin protects low density lipoprotein from oxidative modification. *Heart* 77, 333–337.

39. Suarez-Kurtz, G., Ribeiro, F. M., Estrela, R. C., Vicente, F. L., Struchiner, C. J. (2001) Limited-sampling strategy models for estimating the pharmacokinetic parameters of 4-methylaminoantipyrine, an active metabolite of dipyron. *Braz. J. Med. Biol. Res.* 34, 1475–1485.
40. Volz, M., Kellner, H. M. (1980) Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyron). *Br. J. Clin. Pharmacol.* 10 (Supp. 2), 299S–308S.
41. Uetrecht, J. P., Ma, H. M., MacKnight, E., McClelland, R. (1995) Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. *Chem. Res. Toxicol.* 8, 226–233.
42. Welling, M. M., Mongera, S., Lupetti, A., Balter, H. S., Bonetto, V., Mazzi, U., Pauwels, E. K., Nibbering, P. H. (2002) Radiochemical and biological characteristics of ^{99m}Tc -UBI 29–41 for imaging of bacterial infections. *Nucl. Med. Biol.* 29, 413–422.
43. Webb, C. B., Twedt, D. C., Fettman, M. J., Mason, G. (2003) S-adenosylmethionine (S-AdoMet) in a felineacetaminophen model of oxidative injury. *J. Feline Med. Surg.* 5, 69–75.
44. Wu, R., Lamontagne, D., de Champlin, J. (2002) Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. *Circulation* 105, 387–392.